DRNA News and Press, Dicerna Pharmaceuticals Inc. From 11/22/21

NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New ...

NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) concerning potential violations of the federal securities laws and/or breaches of fiduc...

CyrusOne (CONE) and CoreSite (COR) agreed to be acquired in deals valued at $15 billion and $10 billion, respectively. Data centers have been a significant area of growth over the last couple of decades. Ranked by colocation and data center revenues, CyrusOne and CoreSite are the ...

Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma. AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studi...

Novo Nordisk will acquire Dicerna for $3.3 billion in cash. The acquisition makes sense for Novo Nordisk as it eliminates the milestones and royalties it would need to pay Dicerna for partnered candidates. The deal also brings Dicerna's wholly-owned hepatic and extrahepatic drug d...

Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space, especially with key drugs like Ozempic, Wegovy and Saxenda. RNA interference is...

On a strong day for retailing earnings, BJ’s Wholesale Club (NYSE:BJ) notched one of Thursday's standout performances, expanding its value by a fifth and soaring to a new 52-week high. Elsewhere, Dicerna Pharmaceuticals (NASDAQ:DRNA) stood as another of the day's top gainers. The drug ...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Dicerna Pharmaceuticals, Inc. Enters into a Definitive Agreement to be acquired by Novo Nordisk for USD3.3 Billion” Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) su...

Dicerna Pharmaceuticals ( Nasdaq: DRNA ) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.3 billion, shares in cash of $38.25 each. Both the Board of Directors of N...

Gainers: Longeveron (NASDAQ:LGVN) +137%. Virtuoso (NASDAQ:VOSOU) +89%. Dicerna (NASDAQ:DRNA) +79%. ClearSign (NASDAQ:CLIR) +33%. Alpine (NASDAQ:ALPP) +22%. Macy's (NYSE:M) +21%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +20%. BJ's (NYSE:BJ) +19%. Jowell Global (NASDAQ:JWEL) +17%. Yatsen Holdin...